Report system for intracellular evaluation of nsp3 protein PLpro cleavage activity and related protein and coding gene thereof
By linking a modified GFP reporter protein to the PLpro active protein, GFP-nsp3 and nsp3-GFP cleavage-inducing proteins were constructed, solving the problem that existing technologies cannot fully reflect the membrane localization and protein-protein interactions during the nsp3/4 trans-cleavage process, and enabling more comprehensive screening and evaluation of the effects of PLpro inhibitors.
Patent Information
- Application Number
- CN202411665367.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-20
- Publication Date
- 2026-05-22
AI Technical Summary
Existing screening systems cannot fully reflect the membrane localization and protein-protein interactions in the activity of the PLpro domain of the SARS-CoV-2 nsp3 protein, especially in the process of nsp3/4 trans cleavage, where there is a lack of reporting systems that can indicate these factors.
A reporter system for evaluating the PLpro cleavage activity of the nsp3 protein in cells was designed. By linking a modified GFP reporter protein to the C-terminus or N-terminus of the PLpro active protein, two cleavage-inducing proteins, GFP-nsp3 and nsp3-GFP, were constructed. These proteins can indicate PLpro activity in cells and assess membrane localization and protein-protein interactions during nsp2/3 or nsp3/4 cleavage.
It provides a low-background, multi-target screening system that can screen for PLpro inhibitors and evaluate various factors in the nsp3/4 trans-cleavage process. It has a novel mechanism of action and can more comprehensively reflect the membrane localization and protein-protein interactions in the nsp3/4 trans-cleavage process.
Smart Images

Figure HDA0005144455070000011 
Figure HDA0005144455070000021 
Figure HDA0005144455070000031
Abstract
Description
Technical Field
[0001] This invention relates to the field of genetic engineering technology, and more particularly to the field of a reporting system for the activity of the PLpro domain in the non-structural protein 3 (nsp3) of the novel coronavirus. Background Technology
[0002] The SARS-CoV-2 nonstructural protein 3 (nsp3) is the largest membrane-associated, multifunctional viral protein. It contains a papain-like protease (PLpro) domain that cleaves viral polypeptides and host polyubiquitin chains, crucial for assembling the double-membrane vesicles required for viral replication and evading the host's innate immunity. Therefore, the activity of nsp3 and its PLpro domain is a promising antiviral target.
[0003] Nsp3 is the largest viral protein in coronaviruses, containing over 1900 amino acids and a molecular weight of approximately 200 kDa. It has two transmembrane helices (TM). The N-terminal region of Nsp3, preceding the TM, contains several domains arranged sequentially: ubiquitin-like domain 1 (Ubl1), a hypervariable region (HVR), large domain I (Mac1), large domain II (Mac2), large domain III (Mac3), the domain preceding Ubl2 and PLpro (DPUP), ubiquitin-like domain 2 (Ubl2), a papain-like domain (PLpro), a nucleic acid binding (NAB) domain, and a β-coronavirus-specific marker (βSM) domain. This N-terminal region accounts for approximately two-thirds of the total protein length. The C-terminal region of Nsp3, following the TM, contains the Y1 and CoV-Y domains (Y1&CoV-Y), accounting for approximately one-fifth of the total length (Lei J, Kusov Y, Hilgenfeld R. 2018. Antiviral Res 149: 58-74.). The PLpro recognition sequence motif is “LXGG ↓ XX”, where the tetrapeptide LXGG corresponds to the P4-P1 substrate site (P4-P3-P2-P1) of the cysteine protease (Osipiuk J, Azizi SA, Dvarkin S, et al. 2021. Nat Commun 12:743; Fu Z, Huang B, Tang J, et al. 2021. Nat Commun 12:488). Substrate selection is influenced by residues within the binding pocket; for SARS-CoV-2 PLpro, key residues include Leu162, Asp164, Met208, Pro247, Pro248, Tyr264, Tyr268, G ln269, Cys270, Gly271, and Tyr273. Inhibitors derived from tetrapeptides, such as VIR250 and VIR25, mimic the LXGG structure and possess a vinyl methyl ester group that reacts with catalytic Cys111 (Rut W, LvZ, Zmudzinski M, et al. 2020. Sci Adv 6.). Ubiquitin (Ub) and ISG15 have an LRGG sequence at their C-terminus.PLpro also exhibits deubiquitination and deISGylization activities by cleaving proteins linked to the C-terminus of Ub and ISG15, which may play a role in regulating host innate immunity (Ziebuhr J, Thiel V, Gorbalenya AE. 2001. JBiol Chem 276: 33220-32; Mielech AM, Chen Y, Mesecar AD, Baker SC. 2014. Virus Res194: 184-90; Shin D, Mukherjee R, Grewe D, et al. 2020. Nature 587: 657-662.). SARS-CoV-2 PLpro selectively targets human ISG15 and K48-linked diubiquitin by recognizing two Ub domains or Ub-like (UBL) domains with proximal (S1) and distal (S2) Ub binding sites located outside the substrate-binding pocket (Wydorski PM, Osipiuk J, Lanham BT, et al. 2023. Nat Commun 14: 2366; Bekes M, van der Heden van Noort GJ, et al. 2016. Mol Cell 62: 572-85). Therefore, despite the conservation of the motif recognition sequence, PLpro exhibits substrate selectivity through additional substrate-specific interactions.
[0004] While the cleavage mechanisms of PLpro on ubiquitin (Ub) and ISG15 have been extensively studied, the PLpro-mediated cleavage mechanisms of nsp2 / 3 and nsp3 / 4 remain unclear. Importantly, the interaction between membrane-associated PLpro and membrane-associated substrates requires further investigation. Nsp3 is crucial in the assembly of two-membrane vesicles (DMVs), which contain the replication-transcriptional complex (RTC), essential for viral genome replication and transcription. Studies have shown that nsp3 and nsp4 in SARS-CoV-2 are the minimum components required for DMV assembly; however, nsp3 with silencing mutations at the PLpro active site cannot perform this function (Zimmermann L, Zhao X, Makroczyova J, et al. 2023. Nat Commun 14: 7894). The C-terminus and transmembrane region of SARS-CoV-2 nsp3 polymerize to form a hexameric protein complex called a molecular pore, which spans the double membrane of the DMV and is presumably facilitated by the transport of the nascent viral genome for viral particle assembly (Wolff G, Limpens RWAL, Zevenhoven-Dobbe JC, et al. Science 369:1395-1398). Therefore, cleavage of nsp3 / 4 is crucial for DMV function, and elucidating its molecular mechanism may contribute to the development of novel antiviral agents targeting PLpro and DMV assembly.
[0005] Currently, most screening systems for PLpro activity of nsp3 utilize the PLpro domain alone in combination with a heterologous reporter protein containing a PLpro recognition sequence. No reporter system for the PLpro domain activity of nsp3 has yet been found that can comprehensively reflect various factors of membrane localization and protein-protein interactions during the nsp3 / 4 trans-cleavage process. Summary of the Invention
[0006] To address the aforementioned technical problems, this invention provides a reporting system for evaluating the PLpro cleavage activity of the nsp3 protein within cells, along with its related proteins and encoding genes. This reporting system not only indicates PLpro activity but also various factors affecting membrane localization and protein-protein interactions during the cleavage of SARS-CoV-2 proteins (nsp2 / 3 or nsp3 / 4). Therefore, it features low background and multiple targets, and can be used to screen for PLpro inhibitors of nsp3 within cells, as well as inhibitors targeting the nsp2 / 3 or nsp3 / 4 cleavage process. These inhibitors may possess novel mechanisms of action. Furthermore, this strategy can be applied to the evaluation of the activity of all other coronavirus proteases and other viral proteases.
[0007] The first aspect of the present invention discloses a cleavage-inducing protein for evaluating the PLpro cleavage activity of nsp3 in cells, the cleavage-inducing protein comprising a PLpro active protein and a modified GFP reporter protein linked to the C-terminus or N-terminus of the PLpro active protein; the PLpro active protein comprising at least a PLpro domain and a Y1 domain sequence; the modified GFP reporter protein being selected from a first modified GFP reporter protein or a second modified GFP reporter protein.
[0008] The first modified reporter protein has GFP reporter protein-nsp2 / 3 cleavage sites sequentially from the N-terminus to the C-terminus; the nsp2 / 3 cleavage sites include at least the amino acid sequence LKGGAPT (as shown in SEQ ID NO.7); the C-terminus of the first modified GFP reporter protein is connected to the N-terminus of the PLpro active protein, thus forming a cleavage-inducing protein (referred to as "GFP-nsp3") with GFP reporter protein-nsp2 / 3 cleavage sites-PLpro active protein sequentially from the N-terminus to the C-terminus, which can be used to evaluate the PLpro cleavage activity of nsp3 on nsp2 / 3 in cells.
[0009] The second modified reporter protein consists of an nsp3 / 4 cleavage site (N-degron)-GFP reporter protein from the N-terminus to the C-terminus; the nsp3 / 4 cleavage site is shown in SEQ ID NO.3, or a sequence with more than 99% identity to the sequence shown in SEQ ID NO.3; the N-terminus of the second modified GFP reporter protein is connected to the C-terminus of the PLpro active protein, thus forming a cleavage-inducible protein (hereinafter referred to as "nsp3-GFP") consisting of PLpro active protein-nsp3 / 4 cleavage site-GFP reporter protein from the N-terminus to the C-terminus, which can be used to evaluate the PLpro cleavage activity of nsp3 on nsp3 / 4 in cells.
[0010] Preferably, the amino acid sequence of the nsp2 / 3 cleavage site is LKGGAPT, or has more than 99% identity with LKGGAPT.
[0011] Preferably, the PLpro active protein is the full-length sequence of the nsp3 protein as shown in SEQ ID NO.2, or a sequence that has more than 99% identity with the sequence shown in SEQ ID NO.2.
[0012] Preferably, the PLpro active protein is the nsp3ΔN1C2 mutant protein sequence shown in SEQ ID NO.5, or a sequence with more than 99% identity to the sequence shown in SEQ ID NO.5. The nsp3ΔN1C2 mutant is formed by truncating the nsp3 protein after codon optimization, while retaining the nsp3 / 4 cleavage site.
[0013] Preferably, the amino acid sequence of the GFP reporter protein is as shown in SEQ ID NO.4, or has more than 99% identity with the sequence shown in SEQ ID NO.4.
[0014] Preferably, the cleavage-inducing protein is an intracellular cleavage-inducing protein for evaluating the cleavage activity of PLpro against nsp3 / 4, and the amino acid sequence of the cleavage-inducing protein is selected from CID1 or CID13; the CID1 protein sequence is as shown in SEQ ID NO.1, or has more than 99% identity with the sequence shown in SEQ ID NO.1; the CID2 protein sequence is as shown in SEQ ID NO.6, or has more than 99% identity with the sequence shown in SEQ ID NO.6.
[0015] Preferably, the PLpro active protein is an nsp3 truncated protein that comprises at least a Mac3 domain, a DPUP domain, a Ubl2 domain, a PLpro domain, a NAB domain, a bSM domain, a TM domain, and a Y1 domain from the N-terminus to the C-terminus, including but not limited to nsp3ΔN1C1 and nsp3ΔN1C2.
[0016] Preferably, the cleavage-inducing protein is an intracellular cleavage-inducing protein for evaluating the cleavage activity of PLpro against nsp2 / 3, wherein the cleavage-inducing protein is selected from GFP-nsp3, GFP-nsp3ΔN1C1, or GFP-nsp3ΔN1C2; the amino acid sequence of GFP-nsp3 is as shown in SEQ ID NO.15, or has more than 99% identity with the sequence shown in SEQ ID NO.15; the amino acid sequence of GFP-nsp3ΔN1C1 is as shown in SEQ ID NO.16, or has more than 99% identity with the sequence shown in SEQ ID NO.16; the amino acid sequence of GFP-nsp3ΔN1C1 is as shown in SEQ ID NO.17, or has more than 99% identity with the sequence shown in SEQ ID NO.17.
[0017] A second aspect of the present invention provides a gene encoding the cleavage-inducing protein described in the above-mentioned technical solution. The gene encoding the cleavage-inducing protein includes a gene encoding a PLpro active protein and a modified GFP reporter protein encoding gene linked to the 5' or 3' end of the PLpro active protein. The PLpro active protein encoding gene includes at least the coding sequences of the PLpro domain and the Y1 domain. The modified GFP reporter protein encoding gene is selected from a first modified GFP reporter protein encoding gene or a second modified GFP reporter protein encoding gene. The first modified reporter protein encoding gene includes a GFP reporter protein encoding gene, an nsp2 / 3 cleavage site encoding gene, and a PLpro active protein encoding gene linked sequentially from the 5' to the 3' end. The nsp2 / 3 cleavage site encoding gene is as shown in SEQ ID NO. 18, or has at least 99% identity with the sequence shown in SEQ ID NO. 18. The second modified reporter protein is an nsp3 / 4 cleavage site-GFP reporter protein linked sequentially from the 5' to the 3' end. The nsp3 / 4 cleavage site encoding gene is as shown in SEQ ID NO. 10, or has at least 99% identity with the sequence shown in SEQ ID NO. 10.
[0018] Preferably, the PLpro active protein encoding gene is the full-length nsp3 gene sequence, as shown in SEQ ID NO.9, or has more than 99% identity with the sequence shown in SEQ ID NO.9; or, the PLpro active protein encoding gene is the nsp3ΔNIC2 mutant nucleotide sequence, as shown in SEQ ID NO.12, or has more than 99% identity with the sequence shown in SEQ ID NO.12; or, the PLpro active protein encoding gene includes at least an nsp3 truncated protein with at least the following domains sequentially from the 5' end to the 3' end: Mac3 domain, DPUP domain, Ubl2 domain, PLpro domain, NAB domain, bSM domain, TM domain, and Y1 domain.
[0019] Preferably, the GFP reporter protein encoding gene is as shown in SEQ ID NO.11, or has more than 99% identity with the sequence shown in SEQ ID NO.11.
[0020] Preferably, when the PLpro cleavage-inducing protein is selected from CID1 or CID13, the CID1 protein-coding gene is as shown in SEQ ID NO.8, or has more than 99% identity with the sequence shown in SEQ ID NO.8; the CID13 protein-coding gene is as shown in SEQ ID NO.13, or has more than 99% identity with the sequence shown in SEQ ID NO.13.
[0021] Preferably, when the cleavage-inducing protein is selected from GFP-nsp3, GFP-nsp3ΔN1C1, or GFP-nsp3ΔN1C2, the coding gene of GFP-nsp3 is as shown in SEQ ID NO.19, or has more than 99% identity with the sequence shown in SEQ ID NO.19; the coding gene of GFP-nsp3ΔN1C1 is as shown in SEQ ID NO.20, or has more than 99% identity with the sequence shown in SEQ ID NO.20; and the coding gene of GFP-nsp3ΔN1C2 is as shown in SEQ ID NO.21, or has more than 99% identity with the sequence shown in SEQ ID NO.21.
[0022] A third aspect of the present invention provides an expression vector comprising the coding gene described in any one of the above-described technical solutions. In some specific embodiments of the present invention, the expression vector is constructed using the pLCCMV plasmid.
[0023] The fourth aspect of the present invention provides the use of the cleavage-inducing protein, encoding gene or expression vector described in the foregoing technical solutions in screening PLpro activity inhibitors or evaluating the activity of nsp3 protein in cells; in some preferred embodiments, the cleavage protein is used in evaluating the PLpro cleavage activity of nsp3 against nsp3 / 4 or against nsp2 / 3 in cells.
[0024] A fifth aspect of the present invention provides a reporting system for evaluating the PLpro cleavage activity of nsp3 in cells, comprising the cleavage-inducing protein and GFP detection reagent described in the foregoing technical solutions.
[0025] Preferably, the reporting system further includes an nsp3PLpro inactivating mutant, the amino acid sequence of which is shown in SEQ ID NO. 7, or has more than 99% identity with the sequence shown in SEQ ID NO. 7. In this invention, the coding gene of the nsp3PLpro inactivating mutant is shown in SEQ ID NO. 14, or has more than 99% identity with the sequence shown in SEQ ID NO. 14.
[0026] A sixth aspect of the present invention provides a method for evaluating the PLpro cleavage activity of nsp3 in cells, comprising the following steps:
[0027] S1, Transfect the expression vector described in the aforementioned technical solution into target cells to express the cleavage-inducing protein described in the aforementioned solution in the cells, or co-express the cleavage-inducing protein described in the aforementioned solution and the nsp3 protein in the cells;
[0028] S2, after the target cells have been lysed and expressed, GFP protein is detected by Western blotting.
[0029] Preferably, step S1 further includes: taking another target cell and expressing the PLpro inactivation mutant or co-expressing the PLpro inactivation mutant and nsp3 protein in the target cell as a control group.
[0030] Preferably, when screening for PLpro inhibitors, step S1 further includes: adding the PLpro inhibitor to be tested to a portion of the target cells containing the PLpro cleavage-inducing protein; step S2 further includes: detecting the GFP content in the cleavage product in the target cells with or without the added PLpro inhibitor to be tested, and quantitatively evaluating the inhibitory effect of the PLpro inhibitor to be tested.
[0031] The seventh aspect of the present invention provides an nsp3 protein activity detection protein ubiGFPu, the amino acid sequence of which is shown in SEQ ID NO.22, or has more than 99% identity with the amino acid sequence shown in SEQ ID NO.22.
[0032] The eighth aspect of the present invention provides a gene encoding ubiGFPu, an nsp3 protein activity detection protein, the nucleotide sequence of which is shown in SEQ ID NO.23, or has more than 99% identity with the amino acid sequence shown in SEQ ID NO.23.
[0033] The ninth aspect of the present invention provides the application of the aforementioned nsp3 protein activity detection protein ubiGFPu or its encoding gene in detecting nsp3 protein activity or screening PLpro cleavage activity inhibitors.
[0034] The tenth aspect of the present invention provides a method for screening inhibitors that specifically inhibit PLpro cleavage activity, comprising the following steps:
[0035] (1) Overexpress the nsp3 protein activity detection protein ubiGFPu described in the aforementioned technical solution in target cells;
[0036] (2) Treat the target cells expressed in step (1) with nps3 proteasome inhibitor and the PLpro inhibitor to be tested, respectively;
[0037] (3) The protein in step (2) was cleaved, and GFP was detected by immunoblotting. The changes in GFP content after treatment with the nps3 proteasome inhibitor and the PLpro inhibitor to be tested were compared. If the GFP content did not change significantly after treatment with the PLpro inhibitor to be tested, the PLpro inhibitor to be tested was determined to be an inhibitor that specifically inhibits PLpro cleavage activity.
[0038] Compared with the prior art, the beneficial effects of the present invention are as follows:
[0039] The inventors discovered that PLpro-mediated nsp2 / 3 and nsp3 / 4 cleavage activities are related to the non-PLpro domains of nsp3. Therefore, in some schemes, the full-length nsp3 is used as the basis for constructing reporter proteins. Since PLpro can mediate nsp2 / 3 and nsp3 / 4 cleavage respectively, the inventors linked GFP containing nsp2 / 3 cleavage sites and GFP containing nsp3 / 4 cleavage sites to the N-terminus and C-terminus of nsp3, respectively, forming two reporter proteins: GFP-nsp3 and nsp3-GFP (e.g., ...). Figure 1 As shown in Figure A), the research structure shows that GFP-nsp3 cleavage can occur through cis and trans mechanisms, while nsp3-GFP cleavage mainly occurs through the trans mechanism. Therefore, in order to specifically evaluate the nsp3 / 4 trans cleavage activity, this invention selects to fuse a GFP reporter protein containing an nsp3 / 4 cleavage site to the C-terminus of nsp3.
[0040] In some preferred embodiments, the reporter protein Nsp3-GFPu1 provided by the present invention consists of the full-length nsp3 sequence, the nsp3 / 4 cleavage site sequence, and the reporter protein GFP, from the N-terminus to the C-terminus. The reporter protein Nsp3-GFPu1 can generate an N-terminal degrader within the cell based on cleavage by the viral protease nsp3. Exposure to the N-terminal degrader leads to the degradation of the reporter protein, thereby generating an ON / OFF reporter signal corresponding to the viral protease activity. The cleavage activity against nsp3 / 4 can then be quantitatively assessed by detecting the optical density of the GFP protein.
[0041] The reporter protein provided by this invention serves as a reporter system for the PLpro activity of nsp3. Compared with a reporter system that only uses the PLpro domain, it can more comprehensively reflect various factors of membrane localization and protein-protein interaction during the nsp3 / 4 trans cleavage process. It is a more comprehensive and effective screening system for nsp3 / 4 trans cleavage inhibitors. Attached Figure Description
[0042] Figure 1 The cleavage of the novel coronavirus's NSP3 / 4 strictly relies on trans-cleavage.
[0043] (A) Schematic diagram of nsp3. 3×Flag (red) and GFP-3×Flag are fused to the N-terminus of nsp3. GFP-3×Flag contains a repeating nsp2 / nsp3 cleavage site (LKGG / APT) located between GFP and 3×Flag. Alternatively, GFP is fused to the C-terminus of nsp3, and an nsp4 sequence (KIVNN) is added to create an nsp3 / nsp4 cleavage site. The C856A marker indicates a PLpro inactivation mutation. (B) nsp2 / 3 cleavage reporter gene GFP-nsp3 and nsp3 / 4 cleavage reporter gene nsp3-GFP and its C856A mutant, expressed alone or co-expressed with nsp3 in HEK293T cells, were then analyzed by Western blot (IB) using the antibodies shown 30 hours post-transfection.
[0044] Figure 2 The C-terminal domain of Nsp3 is necessary for the cleavage of Nsp3 / 4.
[0045] (A) Schematic diagram of nsp3. (B) Expression of GFP-nsp3 and its truncated variants in 293T cells, and Western blot analysis (IB) using the antibody shown. Data from two biological replicates of two independent experiments are shown for each group. Protein bands were quantified by densitometric analysis, and cleavage efficiency (Eff_cleavage) was calculated. Mean ± standard error (SEMs) is expressed (n=6). Lysis products (GFP) are indicated by arrows. (C) Expression of Nsp3-GFP and its truncated variants in 293T cells, and Western blot analysis (IB) using the antibody shown. Data from three biological replicates of two independent experiments are shown for each group. Protein bands were quantified by densitometric analysis, and cleavage efficiency (Eff_cleavage) was calculated. Mean ± standard error (SEMs) is expressed (n=6). Uncut precursor (nsp3ΔC1-GFP) and cleavage product (GFP) are indicated by arrows. The expected molecular weight of each protein is shown in green, and cleavage products (GFP, nsp3) are indicated by arrows. The left side shows the migration of the molecular weight standard (in kDa).
[0046] Figure 3 Membrane targeting and protein interaction promote the cleavage of nsp3 / 4.
[0047] (A) Schematic diagram of each nsp3 plasmid, showing only the C-terminal domain. (B) Nsp3-GFP mutant co-expressed with nsp3, nsp3ΔC1, and nsp3PLP in 293T cells, and Western blot analysis (IB) was performed using the antibodies shown. Data from three biological replicates are presented. Protein bands were quantified by densitometry, and cleavage efficiency (Eff_cleavage) was calculated. Mean ± standard deviation (SDs) are used (n=3). The uncut precursor (nsp3ΔC1-GFP), cleavage product (GFP), and nsp3 mutant are indicated by arrows. (C) nsp3.C856A-ΔY234-GFP and (D) nsp3.C856A.ΔC1insNluc-GFP were co-expressed with nsp3, nsp3ΔC1, and nsp3PLP, respectively, and cleavage efficiency (Eff_cleavage) was calculated. Data from three biological replicates are presented. Mean ± standard deviation (SDs) are used (n=3). The uncut precursor, cleavage product (GFP), and nsp3 mutant are indicated by arrows. Statistical analysis was performed between the nsp3 mutant group and the nsp3 group, and the results were as follows: * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant; two-tailed, unpaired t-test. The expected molecular weight of each protein is indicated in green, and the cleavage products (GFP, nsp3) are indicated by arrows. The left side shows the migration of molecular weight standards (in kDa).
[0048] Figure 4 A protease activity reporting system for nsp3 based on the cleavage-induced degron (CID) strategy.
[0049] (A) Schematic diagram of the CID reporter system for nsp3 protease activity, where the nsp3 / 4 cleavage site binds to N-degron. C856A (star marker) indicates a PLpro inactivation mutation. (B) nsp3 fused with degron and nsp3.C856A expressed in 293T cells and observed using fluorescence microscopy 24 hours post-transfection. Representative images from multiple independent experiments are shown. (C) Schematic diagram of the CID reporter system nCoV-CID13, where the nsp3 / 4 cleavage site (ALKGG) is located at the C-terminus of nsp3ΔN1C2(494-1403aa). (D) CID13 expressed in 293T cells treated with different concentrations of GRL-0617 or with DMSO and observed using fluorescence microscopy 30 hours post-transfection. Representative images from multiple independent experiments are shown. (E) Cells in B were analyzed using Western blot (IB) with the specified antibody, and representative images from multiple independent experiments are shown for each group. The protein bands in (F)C were quantified by optical density measurement and plotted as mean ± standard deviation (SDs) (n = 3).
[0050] Figure 5 The CID reporting system has specificity for NSP3 protease inhibitors.
[0051] (A) Schematic diagram of UbiGFP, where ubiquitin (Ubi) is fused with N-degron-GFP. (B) Expression of UbiGFP and CID13 in 293T cells. Six hours post-transfection, cells were treated with 10 μM GRL-0617 and 10 μM MG132 for 24 hours. Representative images from multiple independent experiments are shown, observed under a fluorescence microscope 30 hours post-transfection.
[0052] Figure 6 Structural basis of SARS-CoV-2 nsp3 protease cleavage and characteristics of the CID reporting system. (A) Schematic diagram of the structure of nsp3 (PDB: 8YAX) in the nsp3-4 well complex. The Ubl2 domain (black arrow), papain-like (PLpro) domain, active site of the protease (red arrow), transmembrane helix (TM), and C-terminal Y1 and CoV-Y domains are labeled. (B) Our invented CID system, which consists of a full-length nsp3 fused to an N-degron-modified GFP reporter gene. Effective cleavage at the nsp3 / 4 junction leads to N-degron exposure, resulting in GFP degradation and an OFF signal. A PLpro inhibitor that blocks cleavage produces an ON signal for GFP. This system reflects not only the effect of the inhibitor on the PLpro active site (PLP) but also the trans-cleavage membrane-associated protein-protein interaction (PPI). Detailed Implementation
[0053] In this invention, "nsp3" refers to non-structural protein 3 of the novel coronavirus (SARS-CoV-2), and also includes proteins that have the same function as non-structural protein 3 of the novel coronavirus and have a sequence identity of more than 80%; particularly including proteins that have the same function as non-structural protein 3 of the novel coronavirus and have a sequence identity of more than 95%, 96%, 97%, 98%, or 99%. The nsp3 protein is typically composed of the following domains in sequence: Ubl1, HRV, Mac1, Mac2, Mac3, DPUR, Ubl2, PL2 pro, NAB, bSM, TM, and Y1&CoV-Y.
[0054] This invention constructs a reporter system (amino acid sequence shown in SEQ ID NO.1), comprising the full-length SARS-CoV-2 nsp3 (amino acid sequence shown in SEQ ID NO.2), an N-terminal degrader (amino acid sequence shown in SEQ ID NO.3) fused to the C-terminus of nsp3 to mimic the N-terminus of nsp4, and a reporter gene GFP (amino acid sequence shown in SEQ ID NO.4). When this reporter system is expressed intracellularly, the PLpro protease domain in the nsp3 protein cleaves the nsp3 / 4 cleavage site, exposing the N-terminus of the N-terminal degrader, ultimately leading to the degradation of the N-terminal degrader-dependent reporter gene. This generates an ON / OFF reporter signal corresponding to viral protease activity—nsp3PLpro activity leads to reporter gene degradation (OFF), while PLpro inhibitors inhibit cleavage, leading to reporter gene expression (ON). The SARS-CoV-2 nsp3 / 4 trans-cleavage process involves membrane localization of nsp3PLpro and protein-protein interactions mediated by the C-terminal domain of the viral substrate nsp3. Therefore, this reporting system not only indicates PLpro activity, but also various factors that can affect membrane localization and protein-protein interactions during the trans-cleavage process of the SARS-CoV-2 protein nsp3 / 4. As a result, it has the characteristics of low background and multiple targets, and can be used to screen for SARS-CoV-2 PLpro inhibitors and inhibitors targeting the SARS-CoV-2 nsp3 / 4 trans-cleavage process in cells. These inhibitors may have novel mechanisms of action.
[0055] 1. Cis and trans cleavage of the SARS-CoV-2 Nsp2 / 3 and Nsp3 / 4 sites.
[0056] To investigate nsp2 / 3 and nsp3 / 4 cleavage in a cellular environment, we constructed reporter systems for nsp2 / 3 and nsp3 / 4 cleavage, comprising a full-length nsp3 gene and a GFP gene with nsp2 / 3 and nsp3 / 4 cleavage sites. In the GFP-nsp3 construct, GFP is linked to a repeating nsp2 / 3 cleavage site (LKGG / APT) via its C-terminus and fused to the N-terminus of Flag-nsp3. Figure 1 A). Conversely, in the nsp3-GFP construct, GFP is linked to the nsp4 (KIVNN) peptide via its N-terminus to satisfy the nsp3 / 4 cleavage site and fused to the C-terminus of Flag-nsp3. Figure 1 A). To evaluate the trans-cleavage activity of nsp2 / 3 and nsp3 / 4, we introduced the PLpro inactivation mutant C856A (Osipiuk J, Azizi SA, Dvorkin S, et al. 2021. Nat Commun 12:743), which served as a substrate for trans-cleavage ( Figure 1 A). Immunoblot analysis of cell lysates showed that GFP was efficiently cleaved in both GFP-nsp3 and nsp3-GFP, indicating successful cleavage at the nsp2 / 3 and nsp3 / 4 cleavage sites. No significant GFP cleavage was detected in GFP-nsp3.C856A and nsp3.C856A-GFP cells; however, co-expression with nsp3 promoted efficient cleavage in both cases, demonstrating that nsp3 supplements trans-cleavage activity at the nsp2 / 3 and nsp3 / 4 cleavage sites. Notably, trans-cleavage of GFP-nsp3.C856A and nsp3.C856A-GFP showed significantly enhanced cleavage efficiency with nsp3 co-expression, especially in nsp3.C856A-GFP, where the post-cleavage GFP level was significantly increased. Figure 1 (B and 1C).
[0057] GFP cleavage from GFP-nsp3 and nsp3-GFP can occur via cis (intramolecular) or trans (intermolecular) mechanisms. Intramolecular cleavage can occur at low protein concentrations, while intermolecular cleavage typically requires higher protein concentrations (Hardy WR, Strauss JH. 1989. J Virol 63: 4653-64). To determine the cleavage patterns of nsp2 / 3 and nsp3 / 4, we evaluated the cleavage sensitivity of GFP-nsp3 and nsp3-GFP at different protein doses (using 1000 ng, 500 ng, 250 ng, and 125 ng plasmid / well in a 12-well plate as an example). We transfected HEK293T cells with different amounts of GFP-nsp3 and nsp3-GFP plasmids and subsequently monitored GFP cleavage under each condition. Effective cleavage of GFP-nsp3 was also observed at low transfection doses, as evidenced by the presence of cleaved GFP and nsp3 bands. Conversely, significant cleavage of nsp3-GFP was only observed at higher transfection doses. Figure 1 D). These results indicate that GFP-nsp3 cleavage can occur via both cis and trans mechanisms, while nsp3-GFP cleavage primarily occurs via the trans mechanism. Furthermore, we evaluated nsp3 / 4 cleavage against a real nsp3-4 peptide background. To facilitate nsp4 detection, we fused GFP to the C-terminus of nsp4. After transfecting HEK293T cells with varying amounts of the nsp3-nsp4-GFP plasmid, significant nsp3 / 4 cleavage was observed only in cells transfected with a high dose, as evidenced by the presence of the cleaved nsp4-GFP and nsp3 bands. Figure 1 E). These data indicate that PLpro-mediated cleavage of nsp2 / 3 can occur effectively through both cis and trans mechanisms, but PLpro-mediated cleavage of nsp3 / 4 mainly occurs through trans cleavage.
[0058] The amino acid sequence of nsp3-nsp4-GFP is shown in SEQ ID NO.24, and its encoding gene is shown in SEQ ID NO.25.
[0059] 2. The role of each domain of nsp3 in the nsp2 / 3 and nsp3 / 4 splits.
[0060] Considering that domain interactions outside the PLpro active site can affect the substrate selectivity of doublyin and ISG15, to investigate the roles of domains such as Ubl1 and Y1&CoV-Y in nsp2 / 3 and nsp3 / 4 cleavage, we truncated specific nsp3 domains while preserving the cleavage sites. We first simultaneously truncated the N-terminal domains Ubl1, HVR, Mac1, part of Mac2, and the C-terminal Y1&CoV-Y domain in GFP-nsp3, generating the GFP-nsp3ΔN1C1 mutant (amino acid sequence shown in SEQ ID NO.16, gene sequence shown in SEQ ID NO.20). Simultaneously, we further truncated the transmembrane helix, generating the mutant GFP-nsp3ΔN1C2 (…). Figure 2 A (its amino acid sequence is shown in SEQ ID NO. 17, and its gene sequence is shown in SEQ ID NO. 21). Since the precursor reporter gene contains GFP, and one of the cleavage products is also GFP, anti-GFP immunoblotting can simultaneously detect both the uncleaved precursor and the cleaved GFP, thus assessing cleavage efficiency. We assessed the cleavage efficiency (Eff_cleavage) of nsp2 / 3 and nsp3 / 4 by calculating the molecular ratio between the cleavage product and the total precursor (including uncleaved and cleaved precursor). The cleavage precursor was inferred to be equal to any cleavage product. We quantified the cleaved GFP and uncleaved precursor in cell lysates using anti-GFP immunoblotting, calculating the cleavage efficiency as the ratio of the GFP protein band intensity to the sum of the GFP and precursor intensities (I_GFP / (I_GFP+I_precursor)). We found that the cleavage efficiency of GFP-nsp3 was very high (Eff_cleavage=1) in the nsp2 / 3 cleavage of the reporter gene GFP-nsp3, and the same was true in the truncated mutants GFP-nsp3ΔN1C1 and GFP-nsp3ΔN1C2 (Eff_cleavage=1). Figure 2 B) indicates that truncation did not affect the cleavage efficiency of GFP-nsp3. Subsequently, we truncated the C-terminal Y1&CoV-Y domain in the nsp3 / 4 cleavage reporter gene nsp3-GFP, preserving the nsp3 / 4 cleavage site, generating the nsp3ΔC1-GFP mutant (amino acid sequence as shown in SEQ ID NO.26, gene sequence as shown in SEQ ID NO.27). Further truncation of the transmembrane helix generated the nsp3ΔC2-GFP mutant ( Figure 2A, whose amino acid sequence is shown in SEQ ID NO. 28 and gene sequence is shown in SEQ ID NO. 29). Highly efficient GFP cleavage (Eff_cleavage = 1) was observed in the GFP-nsp3 reporter gene. However, truncating the C-terminal Y1&CoV-Y domain significantly reduced the GFP cleavage efficiency in the nsp3ΔC1-GFP reporter gene (Eff_cleavage = 0.031), while further truncating the transmembrane helix restored GFP cleavage in the nsp3ΔC2-GFP reporter gene (Eff_cleavage = 1). Figure 2 C). These results indicate that the C-terminal Y1&CoV-Y domain plays an important role in membrane-associated cleavage of nsp3 / 4.
[0061] 3. The necessity of PLpro's membrane targeting and protein-protein interactions for nsp3 / 4 membrane-related trans-cleavage.
[0062] To further investigate the mechanism of nsp3 / 4 membrane-associated trans-cleavage, we aimed to explore the minimum regions required in the C-terminal Y1 and CoV-Y domains involved in this process. We constructed nsp3-GFP mutants (nsp3ΔY4-GFP, nsp3ΔY34-GFP, nsp3ΔY234-GFP) with deletions in the C-terminal Y1 and CoV-Y domains. Figure 3 A), and evaluated the cleavage efficiency of nsp3 / 4 in various mutants. All deletion mutants, except nsp3ΔC1-GFP, showed efficient nsp3 / 4 cleavage ( Figure 3 B). It is worth noting that the nsp3ΔY234-GFP mutant, which retains only the Y1 domain ( Figure 3 A, whose amino acid sequence is shown in SEQ ID NO.30 and whose encoding gene is shown in SEQ ID NO.31), can be completely cleaved, indicating that the Y1 domain is sufficient to achieve nsp3 / 4 cleavage. Next, we evaluated the trans-cleavage of nsp3 / 4 in the nsp3ΔY234-GFP mutant. Figure 3 As shown in Figure C, the presence of the Y1 domain effectively restored the trans-cleavage efficiency of nsp3, with an efficiency of 0.889, while the trans-cleavage efficiency of nsp3ΔC1 decreased to 0.777. Conversely, the nsp3.C856A.ΔY234-GFP mutant exhibited low efficiency under PLpro (PLP) cleavage, with an efficiency of 0.193. Figure 3C). This indicates that membrane targeting of PLpro is necessary for achieving efficient membrane-associated trans-cleavage. The restoration of trans-cleavage mediated by the Y1 domain may be due to the restoration of PLP accessibility to the cleavage site, or due to protein-protein interactions mediated by the C-terminal Y1&CoV-Y domain, since the C-terminal Y1&CoV-Y domain promotes self-interactions of nsp3 (Babot M, Boulard Y, Aguda S, et al. 2024. JVirol 98: e0157523). To elucidate these potential mechanisms, we inserted NanoLuc (Nluc) into nsp3.C856A.ΔC1-GFP to obtain nsp3.C856A.ΔC1-insNluc-GFP (amino acid sequence shown in SEQ ID NO.36, encoding gene shown in SEQ ID NO.38), and evaluated its trans-cleavage efficiency. The insertion of Nluc also restored trans-cleavage, with similar effects to the Y1 domain. However, compared to nsp3.C856A.ΔY234-GFP (Eff_cleavage = 0.889), nsp3.C856A.ΔC1-insNluc-GFP showed lower trans-cleavage efficiency in nsp3 (Eff_cleavage = 0.54). Figure 3 (C and 3D). These results indicate that Y1 domain-mediated self-interactions play a crucial role in the trans-cleavage of nsp3 / 4.
[0063] The protein sequence of Nsp3ΔY4-GFP is shown in SEQ ID NO. 30; the gene sequence of Nsp3ΔY4-GFP is shown in SEQ ID NO. 31; the protein sequence of Nsp3ΔY34-GFP is shown in SEQ ID NO. 32; the gene sequence of Nsp3ΔY34-GFP is shown in SEQ ID NO. 33; the protein sequence of Nsp3ΔY234-GFP is shown in SEQ ID NO. 34; the nucleic acid sequence of Nsp3ΔY234-GFP is shown in SEQ ID NO. 35; the protein sequence of nsp3C856A.ΔC1-insNluc-GFP is shown in SEQ ID NO. 36; and the gene sequence of nsp3C856A.ΔC1-insNluc-GFP is shown in SEQ ID NO. 37.
[0064] 4. Design of a cleavage-induced degron (CID) reporter system targeting the SARS-CoV-2 nsp3 protease activity.
[0065] Currently, several reporter systems exist for detecting nsp3PLpro enzyme activity, primarily utilizing substrates containing "LXGG" and PLpro alone, to perform trans cleavage in vitro (Lim CT, Tan KW, Wu M, et al. 2021. Biochemical Journal 478: 2517-2531) or intracellularly (Ma CL, Sacco MD, Xia ZL, et al. 2021. AcsCentral Science 7: 1245-1260). Based on the data we presented above, trans cleavage mediated solely by a single PLpro domain cannot accurately reflect the membrane-related cleavage of viral peptides. Therefore, we aim to establish an "either / or" reporter system for nsp3PLpro enzyme activity that accurately reflects the nsp3 / 4 cleavage of viral peptides. We employed an N-terminal degrader (N-degron) strategy. Through screening, an N-degron sequence (KLFVDTDADTRL SRRVLRDISER) (amino acid sequence shown in SEQ ID NO.3) (Timms RT, Zhang Z, RheeDY, et al. Science 365: eaaw4912) was first fused to the N-terminus of GFP, and then the N-degron-GFP was fused to the C-terminus of nsp3, resulting in plasmid nsp3-GFPu1. The N-degron contains a lysine (K) residue at its N-terminus, which matches the nsp3 / 4 cleavage site. We hypothesize that PLpro-mediated cleavage at the nsp3 / 4 junction will expose the N-degron, thereby leading to GFP degradation. Figure 4 A). A PLpro-inactivating mutant, C856A, was introduced into the reporter system as an uncut control. As expected, nsp3.C856A-GFPu1 showed a strong GFP signal when expressed in HEK293T cells. In contrast, the GFP signal of nsp3-GFPu1 was significantly weakened. Figure 4 B). Immunoblot analysis showed only a weak band corresponding to the cleaved GFPu1, while treatment with the proteasome inhibitor MG132 restored the GFP signal (data not shown), confirming that N-degron-GFP was effectively cleaved and that the cleaved N-degron-GFP underwent effective degradation. We named nsp3-GFPu1 the Cleavage Induced Degron (CID) reporter system. We further optimized the CID system by codon optimization and truncation of the nsp3 coding region to correspond to the nsp3ΔN1C2 mutant, while retaining the nsp3 / 4 cleavage site. The resulting construct was named nCoV-C1D13 (amino acid sequence shown in SEQ ID NO. 6). Figure 4 C). Transient expression of CID13 in HEK293T cells showed extremely weak GFP signaling ( Figure 4 D) indicates effective cleavage and subsequent degradation of nsp3. Subsequently, we treated CID13-expressing cells with the PLpro inhibitor GRL-0617 (Fu Z, Huang B, Tang J, et al. 2021. Nat Commun 12:488) to assess whether this inhibitor could prevent PLpro-mediated cleavage and degradation. The results showed that GRL-0617 restored GFP signaling and increased CID13 protein expression levels in a dose-dependent manner, with a half-maximal inhibitory concentration (IC50) of 1 / 3. 50 The value was 38.13 μM. Figure 4 DF).
[0066] 5. Specificity of the cleavage-induced degradation (CID) reporter system for SARS-CoV-2 nsp3 protease activity.
[0067] Since the CID reporter system relies on proteasome-mediated degradation, we developed a proteasome-active reporter system, ubiGFPu (amino acid sequence shown in SEQ ID NO. 14), to distinguish the effects of inhibitors on the proteasome from their effects on PLP-mediated cleavage. In this construct, UbiN-degron is fused with GFP (… Figure 5 A). As expected, overexpression of ubiGFPu in HEK293T cells led to significant degradation of GFP, which was reversed by MG132 treatment, while the effect of the PLP inhibitor GRL-0617 was minimal. Figure 5 B). MG132 and GRL-0617 also restored GFP signaling in the CID13 system. Notably, cells treated with MG132 showed diffuse GFP signaling, indicating that cleaved GFPu was restored, while cells treated with GRL-0617 showed membrane-associated GFP signaling, suggesting that uncleaved nsp3-GFP was restored. Figure 5 B). Combining the ubiGFPu and CID systems helps distinguish the specific effects of inhibitors on PLpro-mediated cleavage from their effects on the proteasome.
[0068] 6. The structural basis of SARS-CoV-2 nsp3 protease cleavage and the characteristics of the CID reporting system.
[0069] Recently, Ni et al.'s research detailed the structures of nsp3 and nsp4 in SARS-CoV-2 double-membrane vesicles (DMVs) (Huang Y, Wang T, Zhong L, et al. 2024. Nature 633: 224-231). For example... Figure 6 As shown in Figure A, in the pore complex, the S2 site of PLpro is occupied by the Ubl2 domain, while the Y4 region of the Y1&CoV-Y domain interacts with the posterior portion of the S2 site. Therefore, the C-terminus of nsp3 is located on the posterior region of the PLpro active site by the Y4 domain. The positional constraints imposed by the Y1&CoV-Y and Ubl2 domains hinder cis-cleavage. Based on this structure, deletion of the Y1&CoV-Y domain would alleviate this constraint, thereby promoting cis-cleavage. However, only a small amount of cis-cleavage was observed in nsp3ΔC1-GFP. Figure 2 C). Although the introduction of the Y1 domain in nsp3.C856A.ΔY234-GFP fully restored nsp3 / 4 cleavage, this restoration was primarily attributed to trans-cleavage (C). Figure 3 B and 3C). In nsp3ΔC1-GFP and nsp3.C856A.ΔY234-GFP, considering the distances between the membrane-associated cleavage site, the TM domain, and the Y1 domain and the PLpro active site, PLpro needs to undergo a positional or conformational change to reach the cleavage site. Figure 6 A). This change may be influenced by the NAB and βSM structural domains located between nsp3-TM1 and PLpro, which are not visible in this structure. Figure 6 A). The inefficient cis-cleavage observed in nsp3ΔC1-GFP and nsp3.C856A.ΔY234-GFP suggests that conformational changes in the NAB and βSM domains are constrained. For membrane-associated substrates, such as nsp3.C856A.ΔY234-GFP ( Figure 3 C) and nsp3.C856A.ΔC1.inNluc-GFP( Figure 3 D) It was observed that the cleavage efficiency of nsp3PLP was significantly lower than that of full-length nsp3. These findings suggest that membrane binding of PLP enhances trans cleavage of membrane-associated substrates, indicating that membrane targeting is a key mechanism for substrate selection. Notably, although the addition of Nluc restored trans cleavage of nsp3.C856A.ΔC1.inNluc-GFP, its efficiency (Eff_0.541) was lower than that of the addition of the Y1 domain in nsp3.C856A.ΔY234-GFP (Eff_0.889). Figure 3(C and 3D). Given that the Y1 domain mediates the polymerization of nsp3 (Huang Y, Wang T, Zhong L, et al. 2024. Nature 633: 224-231), these findings suggest that membrane-associated protein-protein interactions enhance the trans-cleavage of nsp3 / 4. Therefore, the CID reporting system of this invention not only indicates PLpro activity but also various factors, including those affecting membrane localization and protein-protein interactions during the trans-cleavage of SARS-CoV-2 protein nsp3 / 4. It features low background and multiple targets, and can be used for intracellular screening of SARS-CoV-2 PLpro inhibitors and inhibitors targeting the trans-cleavage process of SARS-CoV-2 nsp3 / 4. Figure 6 B).
[0070] The present invention will now be described in detail with reference to specific embodiments. The methods used in this invention are all conventional molecular biology methods, including molecular cloning, cell transfection, and Western blotting techniques; specific operational details will not be elaborated further.
[0071] Example 1: Construction of a protease activity reporting system for SARS-CoV-2 nsp3 based on the cleavage-induced degron (CID) strategy
[0072] Plasmid pLCCMV-nsp3-GFPu1 (CID1, amino acid sequence as shown in SEQ ID NO.1) Figure 4 This was generated by fusing the N degrader sequence (SEQ ID NO.3: KLFVDTDADTRL SRRVLRDISER) to the C-terminus of SARS-CoV-2 nsp3. A C856A mutation was introduced into pLCCMV-GFPu1-nsp3 and pLCCMV-nsp3-GFPu1, and the plasmids pLCCMV-GFPu1-nsp3.C856A and pLCCMV-nsp3.C856A-GFPu1 were obtained through fusion PCR-mediated mutation. The plasmid pCDH-puro-OptCID13 (amino acid sequence shown in SEQ ID NO.6) was also described. Figure 4 The plasmid pCDH-puro was constructed by assembling a codon-optimized SARS-CoV-2 nsp3ΔN1C2 sequence, flanked by the C-terminal sequence of nsp3 (ALKGG), the N-degrader sequence (KLFVDTDADTRL SRRVLRDISER), and GFP. The assembled fragment was then cloned into pCDH-puro using the EcoRI / BamHI restriction enzyme site. The plasmid pCDH-puro-UbiGFPu (amino acid sequence as shown in SEQ ID NO. 14) Figure 5The Ubi-N-degron-GFP vector was constructed by assembling ubiquitin, N-degrader (KLFVDTDADTRL SRRVLRDISER), and GFP, and then cloned into pCDH-puro using EcoRI / BamHI. All plasmids were validated by Sanger sequencing.
[0073] Example 2: Sensitivity and specificity of the CID reporting system for SARS-CoV-2 nsp3 to nsp3 protease inhibitors
[0074] Based on the data presented above, trans-cleavage mediated by a single PLpro domain cannot accurately reflect the membrane-related cleavage of viral peptides. Our cleavage-induced degron (CID) system, constructed using a strategy based on the N-terminal degron generated by nsp3 / 4 cleavage, contains the full-length nsp3 and accurately reflects the nsp3 / 4 cleavage behavior of the actual viral peptide. PLpro-mediated cleavage at the nsp3 / 4 junction exposes the N-degron, leading to GFP degradation. Figure 4 A). A PLpro-inactivating mutant, C856A, was introduced into the reporter system as an uncut control. As expected, nsp3.C856A-GFPu1 showed a strong GFP signal upon transient transfection expression in HEK293T cells. In contrast, the GFP signal of nsp3-GFPu1 was significantly weakened. Figure 4 B). We further optimized the CID system by codon optimization and truncation of the nsp3 coding region to correspond to the nsp3ΔN1C2 mutant, while retaining the nsp3 / 4 cleavage site. The resulting construct was named nCoV-CID13 (amino acid sequence shown in SEQ ID NO. 6). Figure 4 C). In HEK293T cells, CID13, expressed via transient transfection, exhibited a very weak GFP signal ( Figure 4 D) indicates effective cleavage and subsequent degradation of nsp3. Subsequently, we treated CID13-expressing cells with the PLpro inhibitor GRL-0617 to assess whether this inhibitor could prevent PLpro-mediated cleavage and degradation. The results showed that GRL-0617 restored GFP signaling and increased CID13 protein expression levels in a dose-dependent manner, with a half-maximal inhibitory concentration (1C50) of 38.13 μM. Figure 4 (DF). This describes the CID system of the present invention, which can indicate the activity of PLpro in cells via an "on / off" mode.
[0075] Since the CID reporter system relies on proteasome-mediated degradation, to distinguish whether the benefit of the inhibitor to the CID system is due to its effect on the proteasome, this invention also provides a reporter system, ubiGFPu (amino acid sequence shown in SEQ ID NO. 14), for the separate detection of proteasome activity. In this construct, Ubi-N-degron is fused with GFP (… Figure 5 A). As expected, overexpression of ubiGFPu in HEK293T cells led to significant degradation of GFP, which was reversed by MG132 treatment, while the effect of the PLP inhibitor GRL-0617 was minimal. Figure 5 B). MG132 and GRL-0617 also restored GFP signaling in the CID13 system. Notably, cells treated with MG132 showed diffuse GFP signaling, indicating that cleaved GFPu was restored, while cells treated with GRL-0617 showed membrane-associated GFP signaling, suggesting that uncleaved nsp3-GFP was restored. Figure 5 B). Therefore, combining the ubiGFPu and CID systems helps to distinguish the specific effects of inhibitors on PLpro-mediated cleavage from their effects on the proteasome.
Claims
1. A cleavage-inducing protein for evaluating the PLpro cleavage activity of nsp3 in cells, characterized in that, The cleavage-inducing protein includes PLpro active protein and a modified GFP reporter protein linked to the C-terminus or N-terminus of PLpro active protein. The PLpro active protein includes at least the sequences of the PLpro domain and the Y1 domain; The modified GFP reporter protein is selected from either the first modified GFP reporter protein or the second modified GFP reporter protein; The first modified reporter protein has GFP reporter protein-nsp2 / 3 cleavage sites from N-terminus to C-terminus; the nsp2 / 3 cleavage sites include at least the amino acid sequence LKGGAPT; the C-terminus of the first modified GFP reporter protein is connected to the N-terminus of the PLpro active protein. The second modified reporter protein consists of an nsp3 / 4 cleavage site and a GFP reporter protein, from the N-terminus to the C-terminus; the nsp3 / 4 cleavage site is as shown in SEQ ID NO.3, or a sequence with more than 99% identity to the sequence shown in SEQ ID NO.3; the N-terminus of the second modified GFP reporter protein is connected to the C-terminus of the PLpro active protein.
2. The cleavage-inducing protein for evaluating the PLpro cleavage activity of nsp3 in cells according to claim 1, characterized in that, The PLpro active protein is the full-length nsp3 protein sequence as shown in SEQ ID NO.2, or a sequence having more than 99% identity with the sequence shown in SEQ ID NO.2; or, the PLpro active protein is the nsp3ΔNIC2 mutant protein sequence as shown in SEQ ID NO.5, or a sequence having more than 99% identity with the sequence shown in SEQ ID NO.5; or the PLpro active protein is an nsp3 truncated protein that includes at least, sequentially, a Mac3 domain, a DPUP domain, a Ubl2 domain, a PLpro domain, a NAB domain, a bSM domain, a TM domain, and a Y1 domain from the N-terminus to the C-terminus.
3. The cleavage-inducing protein for evaluating the PLpro cleavage activity of nsp3 in cells according to claim 2, characterized in that, The amino acid sequence of the GFP reporter protein is shown in SEQ ID NO.4, or has more than 99% identity with the sequence shown in SEQ ID NO.4; The nsp2 / 3 cleavage site in the first modified GFP protein is LKGGAPT, or a sequence with more than 99% identity to LKGGAPT.
4. The cleavage-inducing protein for evaluating the PLpro cleavage activity of nsp3 in cells according to any one of claims 1-3, characterized in that, The cleavage-inducing protein is an intracellular cleavage-inducing protein used to evaluate the cleavage activity of PLpro against nsp3 / 4, and the amino acid sequence of the cleavage-inducing protein is selected from CID1 or CID13. The amino acid sequence of CID1 is as shown in SEQ ID NO.1, or has more than 99% identity with the sequence shown in SEQ ID NO.1; The amino acid sequence of CID2 is as shown in SEQ ID NO.6, or has more than 99% identity with the sequence shown in SEQ ID NO.
6.
5. The cleavage-inducing protein for evaluating the PLpro cleavage activity of nsp3 in cells according to any one of claims 1-3, characterized in that, The cleavage-inducing protein is an intracellular cleavage-inducing protein used to evaluate the cleavage activity of PLpro against nsp2 / 3, and the cleavage-inducing protein is selected from GFP-nsp3, GFP-nsp3ΔN1C1 or GFP-nsp3ΔN1C2; The amino acid sequence of the GFP-nsp3 is shown in SEQ ID NO.15, or has more than 99% identity with the sequence shown in SEQ ID NO.15; The amino acid sequence of the GFP-nsp3ΔN1C1 is shown in SEQ ID NO.16, or has more than 99% identity with the sequence shown in SEQ ID NO.16; The amino acid sequence of the GFP-nsp3ΔN1C1 is shown in SEQ ID NO.17, or has more than 99% identity with the sequence shown in SEQ ID NO.
17.
6. A gene encoding the cleavage-inducible protein according to any one of claims 1-5, characterized in that, The coding gene of the cleavage-inducing protein includes the coding gene of the PLpro active protein and the coding gene of the modified GFP reporter protein linked to the 5' or 3' end of the PLpro active protein. The gene encoding the PLpro active protein includes at least the sequence coding sequences of the PLpro domain and the Y1 domain. The modified GFP reporter protein encoding gene is selected from either the first modified GFP reporter protein encoding gene or the second modified GFP reporter protein encoding gene. The first improved reporter protein coding gene includes a GFP reporter protein coding gene, an nsp2 / 3 cleavage site coding gene, and a PLpro active protein coding gene connected sequentially from the 5' end to the 3' end; the nsp2 / 3 cleavage site coding gene is as shown in SEQ ID NO.18, or has at least 99% identity with the sequence shown in SEQ ID NO.18; The second improved reporter protein consists of an nsp3 / 4 cleavage site-GFP reporter protein from the 5' end to the 3' end; the gene encoding the nsp3 / 4 cleavage site is shown in SEQ ID NO.10, or has more than 99% identity with the sequence shown in SEQ ID NO.
10.
7. The encoding gene according to claim 6, characterized in that, The coding gene for the PLpro active protein is the full-length nsp3 gene sequence, as shown in SEQ ID NO.9, or has more than 99% identity with the sequence shown in SEQ ID NO.9; or, the coding gene for the PLpro active protein is the nsp3ΔNIC2 mutant nucleotide sequence, as shown in SEQ ID NO.12, or has more than 99% identity with the sequence shown in SEQ ID NO.12; or, the coding gene for the PLpro active protein includes at least the coding gene for an nsp3 truncated protein whose 5' end to 3' end consists of at least the Mac3 domain, DPUP domain, Ubl2 domain, PLpro domain, NAB domain, bSM domain, TM domain, and Y1 domain, respectively. The GFP reporter protein encoding gene is shown in SEQ ID NO.11, or has more than 99% identity with the sequence shown in SEQ ID NO.
11.
8. The encoding gene according to claim 7, characterized in that, When the PLpro cleavage-inducing protein is selected from CID1 or CID13, the CID1 protein-encoding gene is as shown in SEQ ID NO.8, or has more than 99% identity with the sequence shown in SEQ ID NO.8; the CID13 protein-encoding gene is as shown in SEQ ID NO.13, or has more than 99% identity with the sequence shown in SEQ ID NO.
13. And / or, when the cleavage-inducing protein is selected from GFP-nsp3, GFP-nsp3ΔN1C1, or GFP-nsp3ΔN1C2, the coding gene of GFP-nsp3 is as shown in SEQ ID NO.19, or has more than 99% identity with the sequence shown in SEQ ID NO.19; the coding gene of GFP-nsp3ΔN1C1 is as shown in SEQ ID NO.20, or has more than 99% identity with the sequence shown in SEQ ID NO.20; the coding gene of GFP-nsp3ΔN1C2 is as shown in SEQ ID NO.21, or has more than 99% identity with the sequence shown in SEQ ID NO.
21.
9. An expression carrier, characterized in that, Includes the coding gene as described in any one of claims 6-8.
10. The application of the cleavage-inducing protein according to any one of claims 1-5, the encoding gene according to any one of claims 6-8, or the expression vector according to claim 9 in screening PLpro activity inhibitors or evaluating the activity of nsp3 protein in cells.
11. A reporting system for evaluating the PLpro cleavage activity of nsp3 in cells, characterized in that, Includes cleavage-inducing proteins and GFP detection reagents; The cleavage-inducing protein is the PLpro cleavage-inducing protein according to any one of claims 1-5, or the protein encoded by the coding gene according to any one of claims 6-8.
12. The reporting system according to claim 11, characterized in that, It also includes the nsp3 PLpro inactivation mutant, whose amino acid sequence is shown in SEQ ID NO.7, or has more than 99% identity with the sequence shown in SEQ ID NO.
7.
13. A method for evaluating the PLpro cleavage activity of nsp3 in cells, characterized in that, Includes the following steps: S1, the expression vector of claim 9 is transfected into target cells to express the cleavage-inducing protein of any one of claims 1-5 in the cells, or to co-express the cleavage-inducing protein of any one of claims 1-5 and the nsp3 protein in the cells; S2, after the target cells have been lysed and expressed, GFP protein is detected by Western blotting.
14. The method according to claim 13, characterized in that, Step S1 also includes: Another set of target cells were taken and expressed with PLpro inactivation mutant or co-expressed with PLpro inactivation mutant and nsp3 protein as a control group. The amino acid sequence of the nsp3 PLpro inactivation mutant is shown in SEQ ID NO.7, or has more than 99% identity with the sequence shown in SEQ ID NO.
7.
15. The method according to claim 13 or 14, characterized in that, When screening for PLpro inhibitors is required, step S1 further includes: adding the PLpro inhibitor to be tested to a portion of the target cells containing the PLpro cleavage-inducing protein; Step S2 further includes: detecting the GFP content in the cleavage product in target cells with or without the added PLpro inhibitor, and quantitatively evaluating the inhibitory effect of the PLpro inhibitor.
16. A method for intracellular screening of PLpro inhibitors that specifically inhibit PLpro cleavage activity, characterized in that, Includes the following steps: (1) Overexpress the proteasome activity detection protein ubiGFPu in target cells; The amino acid sequence of ubiGFPu is shown in SEQ ID NO.14, or has more than 99% identity with the amino acid sequence shown in SEQ ID NO.14; (2) Treat the target cells expressed in step (1) with nps3 proteasome inhibitor and the PLpro inhibitor to be tested, respectively; (3) The protein in step (2) was cleaved, and GFP was detected by immunoblotting. The changes in GFP content after treatment with the nps3 proteasome inhibitor and the PLpro inhibitor to be tested were compared. If the GFP content did not change significantly after treatment with the PLpro inhibitor to be tested, it was determined that the PLpro inhibitor to be tested was an inhibitor that specifically inhibited PLpro cleavage activity.
